Gannex Pharma Co., Ltd.

Quick facts

Phase 2 pipeline

• ASC42 5 mg

Phase 1 pipeline

• ASC 41
• ASC42 · Gastroenterology
  ASC42 is a potent and selective FXR agonist that modulates bile acid metabolism and inflammation.
• ASC43F

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Gannex Pharma Co., Ltd. portfolio CI brief
• Gannex Pharma Co., Ltd. pipeline updates RSS